ArticleThe journal of pain2025
Paclitaxel-induced neuroinflammation after systemic administration in male and female mice.
Article in The journal of pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Proteomic Adaptations in the Spinal Cord of a Breast Cancer Model of Paclitaxel-Induced Peripheral Neuropathy.Journal of proteome research · 2026Article
- Supercritical COPharmaceutics · 2026Article
- Behavioral and transcriptional effects of age in HbSS-BERK humanized SCD mice.Journal of sickle cell disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Peripheral neuropathy is one of the most prevalent neurotoxic, dose-limiting side effects of paclitaxel, a chemotherapy agent used widely in solid cancers. The mechanism of paclitaxel-induced peripheral neuropathy (PIPN) is poorly understood, and thus there are no approved treatments currently. Notably, neuroinflammation has been described as a cardinal component in the pathogenesis of PIPN. However, animal studies of PIPN assessing neuroinflammation mediators have mostly focused on gene expression, not protein, and usually in one neuronal tissue and/or at one time point in male mice. Thus, characterization of inflammation mediators at different timepoints, in both sexes, and in different neuronal tissues is critical to understanding PIPN. Paclitaxel (8 mg/kg, i.p.) or vehicle was administered every other day for a total of four injections in male and female C57BL/6J mice. Mechanical and cold sensitivity, nerve conductance, and 22 cytokines and chemokines levels in the dorsal root ganglia (DRG) and spinal cord (SC) were measured at different time points (7, 14, and 21 days) post injections in both sexes. Paclitaxel induced mechanical and cold hypersensitivity and decreased nerve conduction amplitude similarly in both male and female mice. Multiplex cytokine analysis revealed that paclitaxel-induced increase in neuroinflammation is time-, sex-, and tissue- dependent. Our findings provide novel contribution to current knowledge about neuroinflammation as an important mechanism in PIPN. In addition, the results could explain potential mechanistic sex differences in immune pain signaling that can guide precision medicine in the future. PERSPECTIVE: Our study demonstrated that the chemodrug paclitaxel induces nociceptive and physiological changes similarly in male and female mice. However, paclitaxel-induced increase in neuroinflammation is time-, sex-, and tissue- dependent. These findings could pave the way for more effective and personalized management of CIPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.